To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

Sponsor
Ferring Pharmaceuticals
Study ID
NCT07029451
Status
Recruiting
Apply to this trial

Conditions

  • Infertility

Eligibility Criteria

Sex
FEMALE
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is a multi-centre prospective non-interventional trial to assess the pattern of use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice. There will be approximately 2500 patients initiated with REKOVELLE® treatment and enrolled in 30-50 sites in China. The total duration of the study will be approximately 35 months.

Key Dates

First listed
Jun 19, 2025
Start date
Aug 5, 2025
Status verified
Jan 2026
Primary completion
Sep 30, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
2,500 participants (estimated)

Primary Outcome Measure

Live Birth Rate per initiated stimulation cycles [ Time Frame: Up to 15 months ]

Central Contacts

Related Studies